Common Equity (Annual)

Common Equity: The sum of all common equity items.

ADC Therapeutics SA (ADCT) had Common Equity of $-185.83M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$81.36M
Net Income	$-142.62M
Cost of Goods Sold	$5.80M
Gross Profit	$75.56M
Operating Expenses	$202.86M
Operating Income	$-121.50M
Non-Operating Income/Expense	$-20.11M
Pre-Tax Income	$-141.61M
Normalized Pre-Tax Income	$-141.61M
Income after Taxes	$-142.62M
Income from Continuous Operations	$-142.62M
Consolidated Net Income/Loss	$-142.62M
Normalized Income after Taxes	$-142.62M
EBIT	$-121.50M
EBITDA	$-119.62M
Weighted-Average Shares Outstanding (Basic)	127.07M
Weighted-Average Shares Outstanding (Diluted)	127.07M
Earnings per Share (EPS) (Basic)	$-1.12
Earnings per Share (EPS) (Diluted)	$-1.12
Balance Sheet Financials
Current Assets	$306.33M
Property, Plant, and Equipment	--
Long-Term Assets	$16.82M
Total Assets	$323.15M
Current Liabilities	$70.16M
Long-Term Debt	$112.45M
Long-Term Liabilities	$438.82M
Total Liabilities	$508.98M
Common Equity	$-185.83M
Tangible Shareholders Equity	$-185.83M
Shareholders Equity	$-185.83M
Common Shares Outstanding	125.75M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-141.17M
Cash Flow from Investing Activities	$0.40M
Cash Flow from Financial Activities	$150.94M
Beginning Cash	$250.87M
End Cash	$261.34M
Increase/Decrease in Cash	$10.47M
Stock-Based Compensation	$6.91M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.37
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-1.53
Debt to Equity Ratio	-0.62
Gross Margin	92.87%
Operating Margin	-149.34%
EBIT Margin	-149.34%
EBITDA Margin	-147.03%
Pre-Tax Profit Margin	-174.06%
Profit Margin	-175.31%
Free Cash Flow	$-140.78M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.25
Inventory Turnover	1.39
Receiveable Turnover	2.79
Days Sales in Receivables	130.63
Return on Equity	76.75%
Return on Tangible Equity	76.75%
Return on Assets	-44.14%
Return on Investments	194.36%
Book Value Per Share	$-1.48
Free Cash Flow per Share	$-1.11
Operating Cash Flow per Share	$-1.11

Data from Zacks Investment Research, Inc.